I think we are on a massive winner here!
1. Why is NTI so unique?2. Clear commercialisation pathway
- There are lots of cannabis companies focusing on commercialising CBD alone, or a combination of CBD and THC treatments
- NTI is NOT one of these companies. NTI is taking a very different approach, as it has developed a unique formulation which exhibits high CBDA, rare cannabinoids and naturally little to no THC. Effectively, all the best stuff without the cra
3. Safe and effective
- CBD is a homogenised product and the market has become saturated. Other players in the cannabis space will ultimately struggle to patent any of their products, as there isn’t anything unique about them
- If one of these players are ultimately successful in proving their product is both safe and effective, what’s to stop competitors copying their formulation and flooding the market with the same product? The answer appears to be nothing, as these products aren’t patentable. So why would big pharma what to partner or licence these technologies? Put simply, they wouldn’t!
- NTI’s specific formulation is patentable and patent grant is currently pending. This means it will be protected and it won’t be able to be copied. This protection is very attractive to big pharma and other potential licencing partners.
4. NTI is focussing on the massive market of neurological solutions - $$$
- We already knew that NTI’s formulation was safe
- Today’s results prove that NTI’s formulation is also efficacious. This is massive and shouldn’t be understated! To me, this is the ultimate piece of the puzzle. It proves that the NTI formulation actually improves neurological function and these results massively de-risk our commercialisation pathway
- NTI are targeting Autism Spectrum Disorders (ASD) as its first indication. ASD is a massive market of US$2.3. We know the product works in this space
- Alternative treatments currently available have horrible side effects. Whilst we know NTI has an excellent safety profile with little to no side effects, and we now know is also very effective.
- Future market indications are even bigger and more lucrative. The ADHD market and multiple sclerosis markets will be the holy grail for NTI. They are each 10x the size of the ASD market!
- Cerebral palsy and other indications are likely to be eligible for fast tracked approval under the Orphan drug designation
Brian is doing a fantastic job marketing this company. The inbound interest from the investor community is at its highest levels. I’m looking forward to the company rapidly moving forward with the ASD studies to get this product to market ASAP.
Well done to all holders - all the best
